In conclusion, this is the first study to evaluate the safety and biologic effects of a survivin-inhibiting strategy in dogs with spontaneous cancer, which may represent a very useful model for bridging the observed gap between murine preclinical and human clinical studies. Here, BIRC5 is linked to cancer.